Carfilnat Injection (60mg), which contains the active ingredient Carfilzomib, is a potent medication primarily used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. This injectable formulation is designed to inhibit the proteasome, a cellular complex responsible for degrading ubiquitinated proteins, thereby disrupting the survival of cancer cells. Carfilnat Injection is typically administered intravenously and is often used in patients who have received at least one prior therapy for their condition. The composition of Carfilnat Injection includes Carfilzomib as the active ingredient, along with various excipients that facilitate its delivery and stability. This drug is crucial in the management of relapsed or refractory multiple myeloma, providing an essential option for patients who have limited treatment alternatives. Its mechanism of action and targeted approach make it a valuable addition to the therapeutic arsenal against this challenging malignancy.